Abstract
Hypoxia-inducible factor-1 (HIF-1) is a nuclear transcription factor that is upregulated in hypoxia and coordinates the adaptive response to hypoxia by driving the expression of over 100 genes. In facilitating tissues to adapt to hypoxia, HIF-1 may have a role in reducing the cellular damage induced by ischaemia, such as that seen in peripheral arterial disease (PAD), or following acute ischaemic insults such as stroke and myocardial infarction. This therefore raises the possibility of HIF-1 modulation in such contexts to reduce the consequences of ischaemic injury. HIF1 has further been implicated in the pathogenesis of atherosclerosis, abdominal aortic aneurysm (AAA) formation, pulmonary hypertension and systemic hypertension associated with obstructive sleep apnoea. Through a better understanding of the role of HIF-1 in these disease processes, novel treatments which target HIF-1 pathway may be considered. This review summarises the role of HIF-1 in arterial disease, specifically its role in atherosclerosis, ischaemic heart disease, in-stent restenosis following coronary revascularisation, stroke, PAD, AAA formation, pulmonary artery hypertension and systemic hypertension. The potential for exploiting the HIF-1 signalling pathway in developing therapeutics for these conditions is discussed, including progress made so far, with attention given to studies looking into the use of prolyl-hydroxylase inhibitors.
Keywords: Aortic aneurysm, arterial disease, atherosclerosis, hypertension, hypoxia-inducible factor, ischaemic heart disease, prolyl-hydroxylase inhibitor, stroke, angiogenesis, hypoxia-inducible factor-1, obstructive sleep apnea
Current Vascular Pharmacology
Title: Hypoxia-Inducible Factor-1 in Arterial Disease: A Putative Therapeutic Target
Volume: 9 Issue: 3
Author(s): Veeru Kasivisvanathan, Joseph Shalhoub, Chung S. Lim, Amanda C. Shepherd, Ankur Thapar and Alun H. Davies
Affiliation:
Keywords: Aortic aneurysm, arterial disease, atherosclerosis, hypertension, hypoxia-inducible factor, ischaemic heart disease, prolyl-hydroxylase inhibitor, stroke, angiogenesis, hypoxia-inducible factor-1, obstructive sleep apnea
Abstract: Hypoxia-inducible factor-1 (HIF-1) is a nuclear transcription factor that is upregulated in hypoxia and coordinates the adaptive response to hypoxia by driving the expression of over 100 genes. In facilitating tissues to adapt to hypoxia, HIF-1 may have a role in reducing the cellular damage induced by ischaemia, such as that seen in peripheral arterial disease (PAD), or following acute ischaemic insults such as stroke and myocardial infarction. This therefore raises the possibility of HIF-1 modulation in such contexts to reduce the consequences of ischaemic injury. HIF1 has further been implicated in the pathogenesis of atherosclerosis, abdominal aortic aneurysm (AAA) formation, pulmonary hypertension and systemic hypertension associated with obstructive sleep apnoea. Through a better understanding of the role of HIF-1 in these disease processes, novel treatments which target HIF-1 pathway may be considered. This review summarises the role of HIF-1 in arterial disease, specifically its role in atherosclerosis, ischaemic heart disease, in-stent restenosis following coronary revascularisation, stroke, PAD, AAA formation, pulmonary artery hypertension and systemic hypertension. The potential for exploiting the HIF-1 signalling pathway in developing therapeutics for these conditions is discussed, including progress made so far, with attention given to studies looking into the use of prolyl-hydroxylase inhibitors.
Export Options
About this article
Cite this article as:
Kasivisvanathan Veeru, Shalhoub Joseph, S. Lim Chung, C. Shepherd Amanda, Thapar Ankur and H. Davies Alun, Hypoxia-Inducible Factor-1 in Arterial Disease: A Putative Therapeutic Target, Current Vascular Pharmacology 2011; 9 (3) . https://dx.doi.org/10.2174/157016111795495602
DOI https://dx.doi.org/10.2174/157016111795495602 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial [Towards an Ecology of Collective Innovation: Human Variome Project (HVP), Rare Disease Consortium for Autosomal Loci (RaDiCAL) and Data-Enabled Life Sciences Alliance (DELSA)]
Current Pharmacogenomics and Personalized Medicine Effects of Verbascoside Administration on the Blood Parameters and Oxidative Status in Jennies and Their Suckling Foals: Potential Improvement of Milk for Human Use
Endocrine, Metabolic & Immune Disorders - Drug Targets Dietary Small Molecules and Large-Scale Gene Expression Studies: An Experimental Approach for Understanding their Beneficial Effects on the Development of Malignant and Non-Malignant Proliferative Diseases
Current Medicinal Chemistry Inflamm-Aging, Cytokines and Aging: State of the Art, New Hypotheses on the Role of Mitochondria and New Perspectives from Systems Biology
Current Pharmaceutical Design Development of Functional Dark Chocolate by Incorporating Flaxseed (Linum usitatissimum) Oil and Honey with Improved Organoleptic and Textural Attributes
Current Nutrition & Food Science Synthesis and Bioactivities of 2-Azetidinone Derivatives as Cholesterol Absorption Inhibitors
Medicinal Chemistry The Role of Small, Dense Low-Density-Lipoproteins in Non-Coronary Forms of Atherosclerosis
Vascular Disease Prevention (Discontinued) Current Therapeutic Approaches in Inflammatory Bowel Disease
Current Pharmaceutical Design Effects of Mesenchymal Stromal Cells on Diabetic Cardiomyopathy
Current Pharmaceutical Design Substance-Related Disorders and Somatic Symptoms: How Should Clinicians Understand the Associations?
Current Drug Abuse Reviews Factor VIII Levels are Associated with Ischemic Stroke, Stroke Subtypes and Neurological Worsening
Current Neurovascular Research Evaluation of Cardiac Scan in Diagnosing Coronary-artery Disease
Current Medical Imaging Serum Interleukin-33 is a Predictor of Depression in Patients with Acute Ischemic Stroke
Current Neurovascular Research Emerging Therapeutic Approaches Multi-Targeting Receptor Tyrosine Kinases and G Protein-Coupled Receptors in Cardiovascular Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry Fetuin-A: A Multifunctional Protein
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Rational Autologous Cell Sources For Therapy of Heart Failure - Vehicles and Targets For Gene and RNA Therapies
Current Gene Therapy Current Progress in Non-Invasive Imaging of Beta Cell Mass of the Endocrine Pancreas
Current Medicinal Chemistry Obesity and Cardioprotection
Current Medicinal Chemistry Molecular Targets of Diabetic Vascular Complications and Potential New Drugs
Current Drug Targets Dichotomous Life of DNA Binding High Mobility Group Box1 Protein in Human Health and Disease
Current Protein & Peptide Science